ArticleHuman vaccines & immunotherapeutics2026
Age-group differential trends in the incidence of herpes zoster during 2010-2024 using Korean national healthcare claim data.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Current advances in the epidemiology, risk factors, prevention, management, and long-term outcomes of herpes zoster and post-herpetic neuralgia.Frontiers in microbiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster (HZ) results from reactivation of the latent varicella-zoster virus, typically in immunologically weakened adults. Relatively few studies have examined recent trends in the incidence of HZ in Korean populations, including children. Korean national healthcare claim data from 2010 to 2024 were utilized for analyses. HZ incident patients were annually defined as those with the International Classification of Diseases, 10th revision code for HZ. In each year, HZ incidence was estimated using national population statistics. HZ incidence increased from about 10 to 15 per 1,000 people between 2010 and 2024 in Korean populations. However, its pattern substantially varied by age-group: rapidly increased until 2013, but afterward substantially attenuated among adults aged ≥50 y; steadily increased among adults aged 30-40 y; incrementally decreased in children aged 5-19 y; but rapidly increased after 2018 in children aged 0-4 y. HZ incidence in Korean populations increased during 2010-2024 with distinct age-group differential patterns. The recent uprising in HZ incidence among the children aged 0-4 y warrants urgent investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.